Daily Dose - Apr 15th, 2024
 
 
Daily Dose | View online
 
April 15, 2024
Pharma facilities must find a balance between high production output and preventing accidents. Using workwear designed specifically for the pharma industry setting allows companies to protect staff from workplace hazards while also complying with essential regulations related to contamination and risk.
The UK-based biotech received notice that the 2021 deal will be terminated in 180 days.
The review began in July 2023, after two patients in Iceland reported adverse events.
Sponsored
mRNA-LNP manufacturing is fraught with obstacles, resulting in higher program risk, inflated costs, and delayed market release. With the right knowledge, companies can overcome the challenges to de-risk & optimize the path to manufacturing success.